Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

The potential of immune biomarkers to advance personalized medicine approaches for schizophrenia.

Cox D, Chan MK, Bahn S.

J Nerv Ment Dis. 2015 May;203(5):393-9. doi: 10.1097/NMD.0000000000000289. Review.

PMID:
25919386
2.

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders.

Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders.

Aust N Z J Psychiatry. 2005 Jan-Feb;39(1-2):1-30. Review.

PMID:
15660702
3.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
4.

[Therapeutic alliance, a stake in schizophrenia].

Charpentier A, Goudemand M, Thomas P.

Encephale. 2009 Feb;35(1):80-9. doi: 10.1016/j.encep.2007.12.009. Epub 2008 May 19. Review. French.

PMID:
19250998
5.

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.

Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA.

Mol Psychiatry. 2012 Dec;17(12):1206-27. doi: 10.1038/mp.2012.47. Epub 2012 May 15. Review.

PMID:
22584864
6.

Pharmacogenetics and schizophrenia.

Foster A, Miller DD, Buckley P.

Clin Lab Med. 2010 Dec;30(4):975-93. doi: 10.1016/j.cll.2010.07.010. Review.

PMID:
20832661
7.

Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial.

Ritsner MS, Bawakny H, Kreinin A.

Psychiatry Clin Neurosci. 2014 Jun;68(6):432-40. doi: 10.1111/pcn.12150. Epub 2014 Feb 18.

8.

Pharmacogenetics of antipsychotic treatment in schizophrenia.

Pouget JG, Müller DJ.

Methods Mol Biol. 2014;1175:557-87. doi: 10.1007/978-1-4939-0956-8_14. Review.

PMID:
25150876
9.

What do large scale studies of medication in schizophrenia add to our management strategies?

Agius M, Davis A, Gilhooley M, Chapman S, Zaman R.

Psychiatr Danub. 2010 Jun;22(2):323-8. Review.

10.

First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.

Popović I, Ravanić D, Popović V, Vladejić S, Stanojević A, Stojanović M.

Psychiatr Danub. 2011 Dec;23(4):384-8.

11.

[A rare and not very studied disorder: childhood-onset schizophrenia. A case report].

Bailly D, de Chouly de Lenclave MB.

Encephale. 2004 Nov-Dec;30(6):540-7. French.

PMID:
15738856
12.

Heterogeneity of treatment effects in schizophrenia.

Stroup TS.

Am J Med. 2007 Apr;120(4 Suppl 1):S26-31. Review.

PMID:
17403379
13.

Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.

Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O'Keane V, Papakostas G, Vieta E, Zohar J.

Eur Neuropsychopharmacol. 2009 Jul;19(7):520-32. doi: 10.1016/j.euroneuro.2009.04.003. Epub 2009 May 2.

PMID:
19411165
14.

[Dysphagia or dysphagias during neuroleptic medication?].

Chaumartin N, Monville M, Lachaux B.

Encephale. 2012 Sep;38(4):351-5. doi: 10.1016/j.encep.2011.07.002. Epub 2011 Oct 11. French.

PMID:
22980477
15.

Neuroimmune biomarkers in schizophrenia.

Tomasik J, Rahmoune H, Guest PC, Bahn S.

Schizophr Res. 2016 Sep;176(1):3-13. doi: 10.1016/j.schres.2014.07.025. Epub 2014 Aug 12. Review.

PMID:
25124519
16.

[Psychosis: from diagnosis to syndrome].

van Os J, Kapur S.

Ned Tijdschr Geneeskd. 2010;154:A1874. Dutch.

PMID:
20456790
17.

Management of treatment-resistant patients with schizophrenia.

Marder SR.

J Clin Psychiatry. 1996;57 Suppl 11:26-30. Review.

PMID:
8941168
18.

Substance abuse and the management of medication nonadherence in schizophrenia.

Wilk J, Marcus SC, West J, Countis L, Hall R, Regier DA, Olfson M.

J Nerv Ment Dis. 2006 Jun;194(6):454-7.

PMID:
16772865
19.

Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?

Buckley PF, Stahl SM.

Acta Psychiatr Scand. 2007 Feb;115(2):93-100. Review.

PMID:
17244172
20.

Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond.

Meyer U, Schwarz MJ, Müller N.

Pharmacol Ther. 2011 Oct;132(1):96-110. doi: 10.1016/j.pharmthera.2011.06.003. Epub 2011 Jun 15.

PMID:
21704074

Supplemental Content

Support Center